Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
T Cell Therapy Market With a compound annual growth rate (CAGR) of XX% from 2024 to 2033, the worldwide T cell therapy market is projected to reach approximately US$ XX billion by 2033 from its estimated US$ XX billion in 2023. CAR The market for T-cell therapy is expanding as a result of its safety benefits, which include a decreased requirement for harsh chemotherapy and immunosuppression, as well as its proven ability to induce remission even in patients with recurrent cancer, increasing overall survival and opening the door for potentially curative procedures like stem cell transplantation.
Market Overview Market for T cell therapy is expanding quickly due to improvements in cancer treatment methods. With this kind of treatment, a patient's T cells are altered in a lab to specifically target and destroy cancer cells. This method, called chimeric antigen receptor (CAR) T-cell therapy, uses genetically modified T cells to recognize and destroy malignant cells. The procedure comprises removing T cells from the patient's blood, reintroducing them into the patient's circulation after genetically altering them to express particular receptors in the lab. . Adoptive cell therapy is another name for this technique that is being researched for additional cancer types and shows promise in treating blood malignancies. In order to maximize the efficiency of the modified T cells, patients may get radiation therapy and chemotherapy during the 2 to 8 week T-cell transfer therapy procedure. In the end, this novel strategy seeks to strengthen the body's immune response to cancer, perhaps improving patient outcomes and treatment efficacy. .
Key Insights
• North America captured highest the market share. • By therapy type, the CAR T-cell therapy segment generated highest market share. • By indication, the hematologic malignancies segment contributed highest revenue share. • By end user, the hospital segment is expected to grow at a significant rate over the forecast period.
Regional Stance Market for CAR T-cell treatment is anticipated to peak in North America, with the US predicted to take the lead. CAR-T treatments may be available for about 3.9% of US patients with advanced or metastatic cancer, offering a sizable market opportunity. The American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group performed a survey on CAR T-cell treatment practices in order to evaluate the infrastructure and procedures across the country. CAR T-cell therapies have been approved by the FDA to treat certain lymphomas, leukemias, and multiple myeloma; these treatments are usually administered after other forms of treatment have failed. Though promising, CAR T-cell treatment is still difficult to administer; it needs specific knowledge and is only available in a few facilities in Ontario, Canada. Nonetheless, the National Research Council (NRC) is working to improve CAR T-cell therapies that are produced domestically, with an emphasis on patient accessibility and affordability. With the highest projected Compound Annual expansion Rate (CAGR) during the forecast period, the Asia Pacific region is expected to witness substantial expansion in the CAR-T-cell treatment market. The Indian government has undertaken various measures to improve the country's healthcare system. One such program is the National Health Mission, which aims to increase access to medical equipment and encourage community involvement in healthcare decision-making. To further improve access to healthcare, the Ayushman Bharat initiative also offers health insurance coverage for hospitalization in secondary and tertiary care. With only two therapies currently approved by the National Medical Products Administration (NMPA) for CAR-T-cell therapy—axicabtagene ciloleucel (Yescarta) and relmacabtagene autoleucel (Carteyva)—the clinical research landscape in China is changing. This indicates the region's potential for further market expansion and innovation in this field.
Report Highlights By Type
Tumor Infiltrating Lymphocytes (TIL)-based therapy, T Cell Receptor (TCR)-based therapy, and CAR T-cell therapy comprise the segments of the worldwide T-cell therapy market. CAR T-cell therapy is anticipated to lead the market among these categories for the duration of the projection. Clinical trials have shown that CAR T-cell therapy is more effective than conventional treatments, especially when treating specific forms of blood cancer. Using a lab-made gene, this novel technique modifies T-cells to make them capable of identifying and eliminating cancer cells. When standard therapies fail or cancer returns, medical professionals may choose to use CAR T-cell therapy.
By Indication Based on indication, the global market for T-cell therapy is divided into solid tumors, hematologic malignancies, and other disorders. Of these, the hematologic malignancies category is expected to hold a substantial market share for the duration of the forecast. Receptor chimeric antigen T-cell immunotherapy, or CAR-T, makes use of the patient's own T cells that have been modified to express chimeric antigen receptors, which identify antigens linked to tumors and cause the tumor cells to die. Hematologic malignancies have shown encouraging response to CAR-T treatment. Novel approaches to treating cancer have been made possible by recent developments in tumor immunology, namely immune-targeted treatments such as CAR-T cell therapy, antibody-drug conjugates, monoclonal antibodies, and bispecific antibodies. In particular, CAR-T cell therapy has transformed the treatment of hematologic malignancies, producing hitherto unseen outcomes in cases of multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and relapsed/refractory (R/R) B-cell acute lymphocytic leukemia (B-ALL) in recent years. Hospitals and cancer treatment facilities make up the end-user section of the global T-cell therapy market. Over the course of the forecast period, the hospital segment is expected to experience significant expansion. Due to its complexity and specialized nature, CAR T-cell therapy requires knowledge and resources that are predominantly found in hospital settings. After a few weeks, T cells are extracted and altered by specialists before being reinfused into the patient's circulation. Usually, the procedure entails lymphodepletion, in which chemotherapeutic medications are used to lower the quantity of healthy T cells and make room for the injected CAR T cells. The process of injecting CAR T cells into a patient's circulation through an IV or central line usually takes less than 30 minutes at hospitals or specialist cancer treatment facilities.
Market Dynamics Driver Advancements in CAR T Cell Research The market for T cell treatment is expanding due to developments in CAR T cell research, as additional antigens are being explored in clinical trials as possible targets for CAR T cells. Additional tumor antigens that are suitable for targeting by CAR T cells have been found by researchers, which has led to the creation of therapies that target numerous antigens at once. This development represents a major advancement in the treatment of cancer and is driving the market for T cell therapy to grow.
Restraints Challenges in CAR T-cell Therapy Affordability and Access
Due to their complex manufacturing processes and expensive patient-specific production, CAR T-cell treatments confront numerous challenges. Even though cutting-edge techniques like allogeneic CAR T-cells have the potential to save costs, the current high costs—which frequently exceed $400,000 USD and occasionally surpass $1 million USD per patient—along with logistical challenges raise questions about accessibility for patients, payers, and healthcare systems around the world. The production procedure, which includes leukapheresis, genetic engineering using viral vectors, and regulated T cell multiplication, significantly raises these costs and prevents the market for T cell treatment from growing.
Opportunities CAR-T Immunotherapy for Solid Tumors Treatment for leukemia and lymphoma has been transformed by CAR-T cell immunotherapy; yet, its potential to cure a wider range of malignancies, including solid tumors like HNSCCs, is still largely unrealized. Progress in solid tumor CAR-T therapy has been hampered by issues such tumor heterogeneity, a lack of tumor-specific antigens, and immunosuppressive microenvironments. But as CAR-T structural design continues to progress from first to fifth generation, there are encouraging prospects to get over these challenges and extend the use of CAR-T therapy to solid tumors, which will propel the market for T cell therapy.
Recent Development • In February 2024, Astellas and Kelonia Therapeutics entered into a Research and License Agreement to develop novel Immuno-Oncology Therapeutics B-Cell lymphoma • In January 2022, Immunocore announced FDA approval of KIMMTRAK (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma • In March 2023, Adaptimmune Therapeutics plc and TCR² Therapeutics Inc. announced entry into a definitive agreement under which Adaptimmune would combine with TCR² in an all-stock transaction to create a preeminent cell therapy company focused on treating solid tumors • In April 2022, Yescarta received U.S. FDA approval as the first CAR T-cell therapy for the initial treatment of relapsed or refractory Large B-cell Lymphoma (LBCL) source: https://www.gilead.com/news-and-press/press-room/press-releases/2022/4/yescarta-receives-us-fda-approval-as-first-car-tcell-therapy-for-initial-treatment-of-relapsed-or-refractory-large-bcell-lymphoma-lbcl. • In January 2024, Adaptimmune announced U.S. FDA acceptance of Biologics License Application for Afami-cel for the treatment of advanced Synovial Sarcoma with Priority Review
Key Players in the T Cell Therapy Market • Pfizer Inc. • Fate Therapeutics • Sorrento Therapeutics • TCR2 Therapeutics Inc • Bluebird Bio Inc. • Gilead Sciences Inc. • Merck KGaA • Novartis AG • Amgen • Celgene Corporation
Market Segmentation By Therapy Type CAR T-cell Therapy T Cell Receptor (TCR)-based Tumor Infiltrating Lymphocytes (TIL)-based By Indication Hematologic Malignancie Lymphoma Leukemia Myeloma Solid Tumors Melanoma Brain & Central Nervous System Liver Cancer Others By End User Hospitals Cancer Treatment Centers
By Geography North America U.S. Canada Europe Germany France United Kingdom Rest of Europe Asia Pacific China Japan India Southeast Asia Rest of Asia Pacific Latin America Brazil Rest of Latin America Middle East & Africa (MEA) GCC North Africa South Africa Rest of Middle East & Africa
Table of content 1. Introduction 1.1. Report Description 1.2. Research Methodology 1.2.1. Data Mining 1.2.2. Market Modeling and Forecasting 1.2.3. Data Validation 1.2.4. Industry Analysis
4. T Cell Therapy Market by Therapy Type 4.1. Introduction 4.2. T Cell Therapy Market Size and Growth Rate by Therapy Type (2021-2030) 4.3. CAR T-cell Therapy 4.3.1. CAR T-cell Therapy Market Size and Growth Rate (2022 - 2030) 4.4. T Cell Receptor (TCR)-based 4.4.1. T Cell Receptor (TCR)-based Market Size and Growth Rate (2022 - 2030) 4.5. Tumor Infiltrating Lymphocytes (TIL)-based 4.5.1. Tumor Infiltrating Lymphocytes (TIL)-based Market Size and Growth Rate (2021-2030)
5. T Cell Therapy Market by Indication Form 5.1. Introduction 5.2. T Cell Therapy Market Size and Growth Rate by Indication Form (2021-2030) 5.3. Hematologic Malignancie 5.3.1. Hematologic Malignancie Market Size and Growth Rate (2021-2030) 5.4. Lymphoma 5.4.1. Lymphoma Market Size and Growth Rate (2021-2030) 5.5. Leukemia 5.5.1. Leukemia Market Size and Growth Rate (2021-2030) 5.6. Myeloma 5.6.1. Myeloma Market Size and Growth Rate (2021-2030) 5.7. Solid Tumors 5.7.1. Solid Tumors Market Size and Growth Rate (2021-2030) 5.8. Melanoma 5.8.1. Melanoma Market Size and Growth Rate (2021-2030) 5.10. Brain & Central Nervous System 5.10.1. Brain & Central Nervous System Market Size and Growth Rate (2021-2030) 5.11. Liver Cancer 5.11.1. Liver Cancer Market Size and Growth Rate (2021-2030) 5.12. Others 5.12.1. Others Market Size and Growth Rate (2021-2030)
6. T Cell Therapy Market by End User 6.1. Introduction 6.2. T Cell Therapy Market Size and Growth Rate by End User (2021-2030) 6.3. Oral 6.3.1. Oral Market Size and Growth Rate (2021-2030) 6.4. Parenteral 6.4.1. Parenteral Market Size and Growth Rate (2021-2030) 6.5. Topical 6.5.1. Topical Market Size and Growth Rate (2021-2030) 6.6. Others 6.6.1. Others Market Size and Growth Rate (2021-2030)
7. T Cell Therapy Market by End User 7.1. Introduction 7.2. T Cell Therapy Market Size and Growth Rate by End User (2021-2030) 7.3. Hospitals 7.3.1. Hospitals Market Size and Growth Rate (2021-2030) 7.4. Hospital Pharmacies 7.4.1. Hospital Pharmacies Market Size and Growth Rate (2021-2030) 7.5. Cancer Treatment Centers 7.5.1. Cancer Treatment Centers Market Size and Growth Rate (2021-2030)
8. Company Profiles 8.1. Sorrento Therapeutics Inc 8.1.1. Business Overview 8.1.2. Therapy Portfolio 8.1.3. Strategic Developments 8.1.4. Financial Overview
9. List of Tables and Figures Table T Cell Therapy Market Size and Market Share by Therapy Type (2021-2023) Table T Cell Therapy Market Size and Market Share by Therapy Type (2023-2030) Figure CAR T-cell Therapy Market Size and Growth Rate (2021-2030) Figure Tumor Infiltrating Lymphocytes (TIL)-based Market Size and Growth Rate (2021-2030) Figure T Cell Receptor (TCR)-based Market Size and Growth Rate (2021-2030)
Table T Cell Therapy Market Size and Market Share by Indication Form (2021-2023) Table T Cell Therapy Market Size and Market Share by Indication Form (2023-2030) Figure Hematologic Malignancie Market Size and Growth Rate (2021-2030) Figure Lymphoma Market Size and Growth Rate (2021-2030) Figure Leukemia Market Size and Growth Rate (2021-2030) Figure Myeloma Market Size and Growth Rate (2021-2030) Figure Solid Tumors Market Size and Growth Rate (2021-2030) Figure Melanoma Market Size and Growth Rate (2021-2030) Figure Brain & Central Nervous System Market Size and Growth Rate (2021-2030) Figure Liver Cancer Market Size and Growth Rate (2021-2030) Figure Others Market Size and Growth Rate (2021-2030)
Table T Cell Therapy Market Size and Market Share by End User (2021-2023) Table T Cell Therapy Market Size and Market Share by End User (2023-2030) Figure Hospitals Market Size and Growth Rate (2021-2030) Figure Cancer Treatment Centers Market Size and Growth Rate (2021-2030) Table T Cell Therapy Market by Regions (2021-2023) Table T Cell Therapy Market by Regions (2023-2030) Figure North America T Cell Therapy Market Size and Growth Rate (2021-2030) Table North America T Cell Therapy Market by Therapy Type (2021-2023) Table North America T Cell Therapy Market by Therapy Type (2023-2030) Table North America T Cell Therapy by Indication Form (2021-2023) Table North America T Cell Therapy by Indication Form (2023-2030) Table North America T Cell Therapy by End User (2021-2023) Table North America T Cell Therapy by End User (2023-2030) Figure United States T Cell Therapy Market Size and Growth Rate (2021-2030) Table United States T Cell Therapy Market by Therapy Type (2021-2023) Table United States T Cell Therapy Market by Therapy Type (2023-2030) Table United States T Cell Therapy by Indication Form (2021-2023) Table United States T Cell Therapy by Indication Form (2023-2030) Figure Canada T Cell Therapy Market Size and Growth Rate (2021-2030) Table Canada T Cell Therapy Market by Therapy Type (2021-2023) Table Canada T Cell Therapy Market by Therapy Type (2023-2030) Table Canada T Cell Therapy by Indication Form (2021-2023) Table Canada T Cell Therapy by Indication Form (2023-2030) Figure Europe T Cell Therapy Market Size and Growth Rate (2021-2030) Table Europe T Cell Therapy Market by Therapy Type (2021-2023) Table Europe T Cell Therapy Market by Therapy Type (2023-2030) Table Europe T Cell Therapy by Indication Form (2021-2023) Table Europe T Cell Therapy by Indication Form (2023-2030) Table Europe T Cell Therapy by End User (2021-2023) Table Europe T Cell Therapy by End User (2023-2030) Figure Germany T Cell Therapy Market Size and Growth Rate (2021-2030) Table Germany T Cell Therapy Market by Therapy Type (2021-2023) Table Germany T Cell Therapy Market by Therapy Type (2023-2030) Table Germany T Cell Therapy by Indication Form (2021-2023) Table Germany T Cell Therapy by Indication Form (2023-2030) Figure France T Cell Therapy Market Size and Growth Rate (2021-2030) Table France T Cell Therapy Market by Therapy Type (2021-2023) Table France T Cell Therapy Market by Therapy Type (2023-2030) Table France T Cell Therapy by Indication Form (2021-2023) Table France T Cell Therapy by Indication Form (2023-2030) Figure UK T Cell Therapy Market Size and Growth Rate (2021-2030) Table UK T Cell Therapy Market by Therapy Type (2021-2023) Table UK T Cell Therapy Market by Therapy Type (2023-2030) Table UK T Cell Therapy by Indication Form (2021-2023) Table UK T Cell Therapy by Indication Form (2023-2030) Figure Russia T Cell Therapy Market Size and Growth Rate (2021-2030) Table Russia T Cell Therapy Market by Therapy Type (2021-2023) Table Russia T Cell Therapy Market by Therapy Type (2023-2030) Table Russia T Cell Therapy by Indication Form (2021-2023) Table Russia T Cell Therapy by Indication Form (2023-2030) Figure Italy T Cell Therapy Market Size and Growth Rate (2021-2030) Table Italy T Cell Therapy Market by Therapy Type (2021-2023) Table Italy T Cell Therapy Market by Therapy Type (2023-2030) Table Italy T Cell Therapy by Indication Form (2021-2023) Table Italy T Cell Therapy by Indication Form (2023-2030) Figure Rest of Europe T Cell Therapy Market Size and Growth Rate (2021-2030) Table Rest of Europe T Cell Therapy Market by Therapy Type (2021-2023) Table Rest of Europe T Cell Therapy Market by Therapy Type (2023-2030) Table Rest of Europe T Cell Therapy by Indication Form (2021-2023) Table Rest of Europe T Cell Therapy by Indication Form (2023-2030) Figure Asia-Pacific T Cell Therapy Market Size and Growth Rate (2021-2030) Table Asia-Pacific T Cell Therapy Market by Therapy Type (2021-2023) Table Asia-Pacific T Cell Therapy Market by Therapy Type (2023-2030) Table Asia-Pacific T Cell Therapy by Indication Form (2021-2023) Table Asia-Pacific T Cell Therapy by Indication Form (2023-2030) Table Asia-Pacific T Cell Therapy by End User (2021-2023) Table Asia-Pacific T Cell Therapy by End User (2023-2030) Figure China T Cell Therapy Market Size and Growth Rate (2021-2030) Table China T Cell Therapy Market by Therapy Type (2021-2023) Table China T Cell Therapy Market by Therapy Type (2023-2030) Table China T Cell Therapy by Indication Form (2021-2023) Table China T Cell Therapy by Indication Form (2023-2030) Figure Japan T Cell Therapy Market Size and Growth Rate (2021-2030) Table Japan T Cell Therapy Market by Therapy Type (2021-2023) Table Japan T Cell Therapy Market by Therapy Type (2023-2030) Table Japan T Cell Therapy by Indication Form (2021-2023) Table Japan T Cell Therapy by Indication Form (2023-2030) Figure Korea T Cell Therapy Market Size and Growth Rate (2021-2030) Table Korea T Cell Therapy Market by TherapyType (2021-2023) Table Korea T Cell Therapy Market by Therapy Type (2023-2030) Table Korea T Cell Therapy by Indication Form (2021-2023) Table Korea T Cell Therapy by Indication Form (2023-2030) Figure India T Cell Therapy Market Size and Growth Rate (2021-2030) Table India T Cell Therapy Market by Therapy Type (2021-2023) Table India T Cell Therapy Market by Therapy Type (2023-2030) Table India T Cell Therapy by Indication Form (2021-2023) Table India T Cell Therapy by Indication Form (2023-2030) Figure Southeast Asia T Cell Therapy Market Size and Growth Rate (2021-2030) Table Southeast Asia T Cell Therapy Market by Therapy Type (2021-2023) Table Southeast Asia T Cell Therapy Market by Therapy Type (2023-2030) Table Southeast Asia T Cell Therapy by Indication Form (2021-2023) Table Southeast Asia T Cell Therapy by Indication Form (2023-2030) Figure Rest of Asia-Pacific T Cell Therapy Market Size and Growth Rate (2021-2030) Table Rest of Asia-Pacific T Cell Therapy Market by Therapy Type (2021-2023) Table Rest of Asia-Pacific T Cell Therapy Market by TherapyType (2023-2030) Table Rest of Asia-Pacific T Cell Therapy by Indication Form (2021-2023) Table Rest of Asia-Pacific T Cell Therapy by Indication Form (2023-2030) Figure South America T Cell Therapy Market Size and Growth Rate (2021-2030) Table South America T Cell Therapy Market by Therapy Type (2021-2023) Table South America T Cell Therapy Market by TherapyType (2023-2030) Table South America T Cell Therapy by Indication Form (2021-2023) Table South America T Cell Therapy by Indication Form (2023-2030) Table South America T Cell Therapy by End User (2021-2023) Table South America T Cell Therapy by End User (2023-2030) Figure Brazil T Cell Therapy Market Size and Growth Rate (2021-2030) Table Brazil T Cell Therapy Market by Therapy Type (2021-2023) Table Brazil T Cell Therapy Market by Therapy Type (2023-2030) Table Brazil T Cell Therapy by Indication Form (2021-2023) Table Brazil T Cell Therapy by Indication Form (2023-2030) Figure Mexico T Cell Therapy Market Size and Growth Rate (2021-2030) Table Mexico T Cell Therapy Market by Therapy Type (2021-2023) Table Mexico T Cell Therapy Market by Therapy Type (2023-2030) Table Mexico T Cell Therapy by Indication Form (2021-2023) Table Mexico T Cell Therapy by Indication Form (2023-2030) Figure Columbia T Cell Therapy Market Size and Growth Rate (2021-2030) Table Columbia T Cell Therapy Market by Therapy Type (2021-2023) Table Columbia T Cell Therapy Market by Therapy Type (2023-2030) Table Columbia T Cell Therapy by Indication Form (2021-2023) Table Columbia T Cell Therapy by Indication Form (2023-2030) Figure Rest of South America T Cell Therapy Market Size and Growth Rate (2021-2030) Table Rest of South America T Cell Therapy Market by Therapy Type (2021-2023) Table Rest of South America T Cell Therapy Market by Therapy Type (2023-2030) Table Rest of South America T Cell Therapy by Indication Form (2021-2023) Table Rest of South America T Cell Therapy by Indication Form (2023-2030) Figure Middle East and Africa T Cell Therapy Market Size and Growth Rate (2021-2030) Table Middle East and Africa T Cell Therapy Market by Therapy Type (2021-2023) Table Middle East and Africa T Cell Therapy Market by Therapy Type (2023-2030) Table Middle East and Africa T Cell Therapy by Indication Form (2021-2023) Table Middle East and Africa T Cell Therapy by End User (2021-2023) Table Middle East and Africa T Cell Therapy by End User (2023-2030) Figure Saudi Arabia T Cell Therapy Market Size and Growth Rate (2021-2030) Table Saudi Arabia T Cell Therapy Market by Therapy Type (2021-2023) Table Saudi Arabia T Cell Therapy Market by Therapy Type (2023-2030) Table Saudi Arabia T Cell Therapy by Indication Form (2021-2023) Table Saudi Arabia T Cell Therapy by Indication Form (2023-2030) Figure United Arab Emirates T Cell Therapy Market Size and Growth Rate (2021-2030) Table United Arab Emirates T Cell Therapy Market by Therapy Type (2021-2023) Table United Arab Emirates T Cell Therapy Market by Therapy Type (2023-2030) Table United Arab Emirates T Cell Therapy by Indication Form (2021-2023) Table United Arab Emirates T Cell Therapy by Indication Form (2023-2030) Figure South Africa T Cell Therapy Market Size and Growth Rate (2021-2030) Table South Africa T Cell Therapy Market by Therapy Type (2021-2023) Table South Africa T Cell Therapy Market by Therapy Type (2023-2030) Table South Africa T Cell Therapy by Indication Form (2021-2023) Table South Africa T Cell Therapy by Indication Form (2023-2030) Figure Rest of Middle East and Africa T Cell Therapy Market Size and Growth Rate (2021-2030) Table Rest of Middle East and Africa T Cell Therapy Market by Therapy Type (2021-2023) Table Rest of Middle East and Africa T Cell Therapy Market by Therapy Type (2023-2030) Table Rest of Middle East and Africa T Cell Therapy by Indication Form (2021-2023) Table Rest of Middle East and Africa T Cell Therapy by Indication Form (2023-2030)
Table Olympus Corporation T Cell Therapy Financial Overview Table Pfizer Inc. T Cell Therapy Financial Overview Table Fate Therapeutics. T Cell Therapy Financial Overview Table Boston Scientific Corporation T Cell Therapy Financial Overview Table Sorrento Therapeutics T Cell Therapy Financial Overview Table TCR2 Therapeutics Inc T Cell Therapy Financial Overview Table Bluebird Bio Inc. T Cell Therapy Financial Overview Table Gilead Sciences Inc. T Cell Therapy Financial Overview Table Merck KGaA T Cell Therapy Financial Overview Table Novartis AG T Cell Therapy Financial Overview Table Amgen. (US) T Cell Therapy Financial Overview Table Celgene Corporation T Cell Therapy Financial Overview
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of T Cell Therapy and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of T Cell Therapy Market for the past year and forecasts for the next six years.T Cell Therapy Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different T Cell Therapy Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for T Cell Therapy from different application industries in different regions.
Market Segmentation By Therapy Type CAR T-cell Therapy T Cell Receptor (TCR)-based Tumor Infiltrating Lymphocytes (TIL)-based By Indication Hematologic Malignancie Lymphoma Leukemia Myeloma Solid Tumors Melanoma Brain & Central Nervous System Liver Cancer Others Others By End User Hospitals Cancer Treatment Centers
By Geography North America U.S. Canada Europe Germany France United Kingdom Rest of Europe Asia Pacific China Japan India Southeast Asia Rest of Asia Pacific Latin America Brazil Rest of Latin America Middle East & Africa (MEA) GCC North Africa South Africa Rest of Middle East & Africa
